Professor Daniela Ferreira at Global Citizen Live 2021
On Saturday, September 25, Global Citizen will present GLOBAL CITIZEN LIVE, a 24 hour global broadcast and streaming event featuring a lineup of artists, with performances from all over the world, including: Lagos, Paris, New York City, London, Sydney, Seoul, Rio de Janeiro, Los Angeles and Mumbai
World leaders, partners, activists, artists, and everyday Global Citizens, Global Citizen Live will be a movement uniting the world to defend the planet and defeat poverty.
Together, they will be calling for action to prioritize vaccine equity, feed millions who are facing famine, and curb climate change through the Trillion Trees Movement.
LSTM's Professor Daniela Ferreira will be participating in the event talking about vaccine equity and how we need to give more vaccines to low- and lower-middle income countries.
Head of Clinical Sciences Department, Professor of respiratory vaccines and infection immunology
Daniela is a global leader in Respiratory Infections and Controlled Human Infection Challenge with experience in bacterial challenge, co-infection studies, mucosal immunity (nose and lungs) and vaccine testing and immune responses. She leads a Programme of work on respiratory infections and accelerated vaccine development with over £20million from various funders including BMGF, MRC, UKRI, NIHR and several industry partners. She leads the unique Experimental Human Pneumococcal Consortium in partnership with over 50 laboratories of worldwide experts on respiratory infection and pneumococcal biology. To date her team has safely challenged over 1800 participants with live bacteria in over 30 clinical studies in their bespoke research clinic at the Accelerator. To find out more about the studies look here.
Her team has played a substantial role in the UK covid-19 pandemic response as a trial site for several covid vaccine studies including the Oxford / Astrazeneca vaccine.
Her research focuses mainly on:
- Accelerate development and test novel pneumococcal vaccines using experimental carriage
- understanding nasal and lung immune responses and correlates of protection against respiratory infection with viruses including SARS-CoV2 and bacteria
- defining how respiratory virus co-infections (flu, RSV and SARS-CoV2) and host susceptibility (asthma, COPD, aging, smoke) alters responses to pneumococcal infection.